

APPLICATION FOR U.S. LETTERS PATENT


for:

**METHOD FOR OBTAINING IN VITRO RECOMBINED
POLYNUCLEOTIDE SEQUENCES, SEQUENCE BANKS
AND RESULTING SEQUENCES**

BY:
Daniel DUPRET et al.

**NIXON PEABODY LLP
8180 Greensboro Drive
Suite 800
McLean, Virginia 22102
(703) 790-9110**

Attorney Docket No.: 746220-000005



PROCESS FOR OBTAINING RECOMBINED NUCLEOTIDE SEQUENCES
IN VITRO, LIBRARIES OF SEQUENCES AND SEQUENCES THUS
OBTAINED

5 The present invention relates to a method of obtaining recombined
nucleotide sequences *in vitro*. The invention is particularly aimed at
generating and then selecting polynucleotide sequences which are liable to
have one or several advantageous properties as compared to the
corresponding properties of reference sequences and therefore capable of
10 conferring an improved phenotype and/or of producing improved proteins.

By reference sequence is understood a sequence having properties
close to those being sought.

15 Different techniques have been developed in order to favor the *in vitro*
recombination between different polynucleotide sequences, among which can
be more particularly cited DNA-shuffling (12) and StEP (14), both based on
the use of PCR.

20 DNA-Shuffling comprises two steps, the random fragmenting by
DNase I of polynucleotide sequences, and an amplification by PCR in which
the fragments previously generated serve as primers. At each step of
hybridization, the change of template provokes recombinations at the level of
the regions having homologous sequences. A schematic representation of
25 this method is provided in figure 1A .

The step consists of mixing different polynucleotide sequences
containing various mutations in the presence of a pair of primers. This
mixture is subjected to a PCR type of reaction in which the hybridization and
30 polymerization steps are grouped together in a single step of very short
duration. These conditions permit hybridization of primers but reduce the
duration hence the length of polymerization, in such a way that the fragments
which are partially synthesized are randomly hybridized to the polynucleotide

sequences having different mutations, thus permitting the recombination. A schematic representation of this method is provided at figure 1B.

In each of these two methods, the polymerization step is indispensable to the process of recombination. Thus, according to the polymerase chosen, this polymerization step can bring about undesired supplemental mutations. Moreover, the DNA-shuffling and the step procedures rest on the principle of the hybridization of a "mega-primer" (6) to a template, which likely leads to difficulties in implementation for polynucleotide sequences of size greater than 1.5 kbp (11). Finally, these two techniques do not permit the control of the rate of recombination, since they are made randomly in the course of successive polymerization steps.

The present invention solves the disadvantages described above by offering a simple method for the preparation of recombined polynucleotide sequences, permitting the generation of polynucleotide sequences capable of displaying advantageous properties as compared to the corresponding properties of the sequences of reference and therefore capable of conferring an improved phenotype and/or producing improved proteins.

This goal is attained thanks to a *in vitro* process for obtaining recombined nucleotide sequences starting from a library of polynucleotide sequences, also designated hereinafter as the initial library, characterized in that it includes the following steps:

- a) fragmenting a library of double-stranded polynucleotide sequences,
- b) the denaturation of fragments possibly in the presence of one or several assembling templates,
- c) the hybridization of said fragments with one or several assembling templates if the template/templates is/are not present in step (b),

- d) the ligation of said fragments in order to obtain recombined polynucleotide sequences,
- e) the selection of recombined nucleotide sequences having advantageous properties as compared to the corresponding properties of one or several reference sequences.

The process of the invention can include at the output of step (d) and before step (e), the repeating of steps (b), (c) and (d) no longer with the fragments of step (a) but with the products of step (d).

This embodiment is particularly useful in the case where, at the outlet of step (d) all the fragments are not ligated. In this case, the process of the invention moreover includes, at the end of step (d) and before step (e), one or several of the following reaction cycles:

- denaturation of the ligated and non-ligated fragments coming out of step (d), possibly in the presence of one or several assembling templates.
- hybridization of said fragments with one or several assembling templates if it (they) is(are) not present at the time of the denaturation,
- ligation of said fragments.

These denaturation, hybridization and ligation reactions are equivalent in steps (b), (c) and (d) but carried out not with the fragments of step (a) but with the ligated and non-ligated fragments coming out of step (d).

The process of the invention can moreover include one or several of the following steps:

- the separation of the recombined polynucleotide sequences from the assembling template or templates before step (e),
- the amplification of the double-stranded recombined polynucleotide sequences before step (e).

- the cloning of the recombined polynucleotide sequences possibly after separation of the recombined strands from the template or templates and obtaining of the corresponding double strand before step (e).

5 The ends of the fragments generated at step (a) are such that there can be adjacent hybridization of these ends to the assembling template or templates at step (c) and ligation of these fragments with each other at step (d). The polynucleotide sequences of the library on which the process of the invention is carried out must include zones of homology either between them
10 or with the assembling templates, so as to permit the generating of the ends of the fragments such as described above.

One advantageous embodiment of the process of the invention consists in simultaneously carrying out steps (c) and (d) according to a
15 reaction called RLR for the English expression of "Recombining Ligation Reaction."

Besides the advantages previously indicated, the process of the invention is notable in that it favors and accelerates the random recombination
20 *in vitro* of polynucleotide sequences and these polynucleotide sequences can be genes. By gene is understood a DNA fragment or sequence associated with a biological function. A gene can be obtained in different manners, such as chemical synthesis, synthesis by polymerization or by extraction of said gene starting with a source of nucleic acids.

25 The *in vitro* recombination of the polynucleotide sequences of the initial library by the process of the invention therefore permits the obtaining of a new library containing sequences having acquired one or several characteristics of the sequences of the previous library. The process of the invention therefore
30 comprises an *in vitro* technique of evolution.

The process of the invention comprises an alternative to recombinant PCR such as implemented in the techniques of DNA shuffling (12) or of StEP

(14), since it does not require the *in vitro* polymerization step in order to end up with the recombination. To the contrary, the key step of the process of the invention is the step (d) of ligation on an assembling template, which assures a very high degree of faithfulness in the course of the recombination events.

5

The process of the invention is notable in that it permits a considerable increase in the efficiency of the reassembling of the fragments to ligate. In effect, in the case of a sequence cut up into n fragments, there exists n^n possibilities of reassociation of the fragments by using a classical process of ligation (without using a reassembling template which directs the ligation), among which a single form is of interest. In the case of the process of the invention, the ligation is directed by the assembling template, which permits to direct obtention of the single form of interest.

10
15

The fragmenting of these polynucleotide sequences at step (a) can be done either in a controlled manner or in a random manner.

20
25

In the case of a fragmenting carried out in a controlled manner, the fragmenting permits controlling with precision the degree of desired recombination and the position of the points of recombination. According to a preferred embodiment of the process of the invention, step (a) consists of subjecting the polynucleotide sequences of the library to hydrolysis by the action of one or several restriction enzymes. In this way, in one particular embodiment of the process of the invention, the degree of recombination and the position of the points of recombination of the recombined polynucleotide sequences are determined by the fragmenting of step (a).

30

Thus, the larger the number of fragments generated by the sequence, the higher the number of fragments necessary to recompose a sequence, which leads to a higher rate of recombination. Moreover, the nature and the position of the ends of the fragments generated in this embodiment of the process of the invention can be known and controlled, which permits:

- controlling with precision the zones where the recombination takes place, or
- inducing recombination between polynucleotide sequences, for example genes, if the ends of the fragments are created in zones of homology between these sequences, or in zones of homology between these sequences and the assembling template or templates.

10 In the case of a random fragmenting, any enzymatic or mechanical means known to a person skilled in the art allowing a random cutting of the double-stranded DNA can be used, such as for example DNase I digestion or sonication.

15 The process of the invention, which permits a considerable increase in the efficiency of reassembling fragments to be ligated, can therefore be applied to the directing of blunt end multi-molecular ligation. In this application, single or double-stranded oligonucleotides complementary only to the 3' end of a fragment and 5' of the adjacent fragment are used as the assembling template in steps (b) or (c), which permits adjacent hybridization of these two ends on the same template after the denaturation step. Once hybridized, the ends of the fragments can be ligated so as to direct the direction of the ligation of the blunt ended fragments. The same approach can be contemplated for the positioning of the ligation of fragments having sticky ends.

25

An especially preferred embodiment of the process of the invention consists of adding at step (c) and/or at step (d) enzymes capable of recognizing and of cutting in a specific manner the non-hybridized ends of fragments, when these overlap with other hybridized fragments on the same template. A preferred example of this type of enzyme is the Flap endonuclease enzyme (10).

30

A particular embodiment of the process of the invention therefore consists of using enzymes of the Flap endonuclease type when the fragments generated at step (a) can be overlapping during the hybridization on the assembling template (of) at step (c).

5

In this way, during the hybridization of single stranded DNA fragments on a template, these enzymes have the property of recognizing and of cutting, in a specific manner, the non-hybridized ends of these fragments, when they overlap with other hybridized fragments on the same template. In the course of the hybridization step (c), these enzymes therefore permit increasing the number of adjacent ends that can be ligated at step (d), which is particularly important in the case of fragments obtained by random cutting, as these fragments have zones overlapping with each other when they are hybridized on the assembling template.

15

In a particular embodiment of the process of the invention using a ligase active at high temperature and preferably thermostable at step (d), the endonucleases, capable of recognizing and of cutting in a specific manner the non-hybridized ends of the fragments such as the Flaps, added at step (c) and/or at step (d) will have the same properties of thermoresistance and of high temperature activity as said ligase.

20

The library of polynucleotide sequences on which the process of the present invention is carried out can be generated by any method known to a person skilled in the art, for example starting with a wild type gene, by successive steps of directed mutagenesis, by "error prone" PCR (2), by random chemical mutagenesis, by random *in vivo* mutagenesis, or by combining genes of close or distinct families within the same species or different species so as to obtain a variety of polynucleotide sequences in said library.

30

Among these techniques, the invention more particularly contemplates a process in which the library of double-stranded polynucleotide sequences is

obtained by a polymerization chain reaction carried out under conditions that permit creation of random point mutations.

5 The initial library of double-stranded polynucleotide sequences can be composed of synthetic sequences which will be fragmented at step (a) or which can be the fragments of step (a).

10 According to a preferred embodiment for carrying out the process of the invention, step (a) consists of subjecting the polynucleotide sequences of the library to hydrolysis by the action of one or several restriction enzymes.

15 In order to increase the degree of recombination generated by the process of the invention, it is sufficient to increase the number of restriction fragments by using restriction enzymes having a large number of cutting sites on the polynucleotide sequences of the library, or by combining several restriction enzymes. In the case of using a thermostable and thermoactive ligase, the size of the smallest fragment thus generated will advantageously be greater or equal to 40 bp, in order to retain a hybridization temperature compatible with that of the ligation step (d) which is generally of the order of
20 65°C.

25 Step (a) can also be carried out by generating a library of fragments by random enzymatic or mechanical treatment. In particular, step (a) can consist of a random treatment with DNase I of a library of partially heterologous double-stranded polynucleotide sequences. In the case where a random enzymatic or mechanical fragmenting is used in step (a), this embodiment of the process of the invention has the characteristic of permitting the use of fragments generated by this treatment as templates for each other, for the hybridization in the course of step (c) or of the RLR reaction of the steps (c)
30 and (d) simultaneously.

Step (b) can be carried out by combining at least two distinct libraries of fragments separately generated at step (a) starting from the same initial library by different treatments, as for example with different restriction enzymes. In the case of the embodiment of such libraries, the fragments
5 obtained at step (a) are used as templates for each other, for the hybridization during the course of step (c) or the RLR reaction of steps (c) and (d) simultaneously.

The fragments of step (a) of the process of the invention can be equally
10 generated by amplification reactions such as PCR realized on the polynucleotide sequences of the library. Two solutions are contemplated. In a first case, the oligonucleotide primers can be conceived in a manner so as to generate fragments having ends which are adjacent all along the length of the assembling sequence. In a second case, the oligonucleotide primers are
15 conceived in a fashion so as to generate fragments having common sequences, these fragments being capable of serving as an assembling template for each other at step (b) or at step (c). The process of the invention permits the combining in a random manner of different fragments obtained at step (a) and of reassembling them during steps (b), (c) and (d) within a
20 polynucleotide sequence. This process therefore reproduces *in vitro* the recombination phenomena which can occur *in vivo* by favoring them. The process of the invention is therefore particularly of interest above all for recombining polynucleotide sequences among themselves in order to generate new polynucleotide sequences having interesting properties as
25 compared to the corresponding properties of the reference sequences.

The effectiveness of the recombination of the process of the invention depends on the number of fragments generated by a polynucleotide sequence at step (a). Consequently, the process of the invention will use
30 polynucleotide sequences having been fragmented into n fragments, n advantageously being greater or equal to three.

The assembling template of step (b) or (c) is for example a polynucleotide sequence coming from the initial library or a consensus sequence of said library, single or double-stranded. In the case where the assembling template is incorporated directly at step (c) of the invention, this
5 template must be single-stranded.

According to a variant of the process of the invention, the assembling templates of steps (b) or (c) are composed of single or double-stranded oligonucleotides.

10

According to a particular embodiment of the process of the invention, oligonucleotides, single or double-stranded, of variable length, are added at step (b) or (c) in addition to the template. These oligonucleotides are designed (to be capable of being) so as to be substituted for a portion of the
15 fragments of step (c), in effect, their sequence is such that:

- if they are perfectly homologous with the sequence of the fragment which they are replacing, they favor certain combinations, or
- 20 - if they are partially heterologous with the sequence of the fragment that they are replacing, they introduce one or a more directed supplemental mutations.

Before step (e) of the process of the invention, it is possible to separate
25 the recombined polynucleotide sequences from the assembling template thanks to a labeling present in the assembling template or in the recombined polynucleotide sequences. It is in effect possible to label each strand of the template according to techniques known to a person skilled in the art. For example, the label of the assembling template can be a hapten and the
30 recombined polynucleotide sequences template are separated from the assembling template by techniques known to a person skilled in the art, such as for example an anti-hapten antibody bound on a support or a biotin-streptavidine reaction, if the hapten is a biotin label.

Other techniques can be employed in order to separate the recombined polynucleotide sequences from the assembling template. The assembling template can also be prepared specifically in a way so as to facilitate its elimination at the end of the process of the invention. It can thus be synthesized by PCR amplification using methylated dATP, which permits its degradation by the restriction endonuclease *Dpn* I. In this case, the recombined polynucleotide sequences must not contain methylated dATP. The template can also have been prepared by PCR amplification by using dUTP, which permits its degradation by treatment with a uracyl-DNA-glycosylase. Conversely, it is possible to protect the recombined polynucleotide sequences by amplifying them by selective PCR with oligonucleotides having 5' phosphorothioate groups. A treatment with an exonuclease then permits the specific digestion of the assembling template.

The process of the invention can include before the possible cloning of step (e), a step of amplification of the recombined polynucleotide sequences. Any amplification technique is acceptable, notably a PCR amplification. One of the most simple consists of carrying out a PCR which permits specific amplification of the recombined polynucleotide sequences owing to primers which can only be hybridized at the ends of the recombined sequences. The PCR products are then cloned in order to be characterized and the polynucleotide sequences having advantageous properties as compared to the corresponding properties of the reference sequences are selected.

The invention has for its object the generation of polynucleotide sequences liable to have advantageous properties as compared to the corresponding properties of reference sequences. The recombined polynucleotide sequences obtained at step (d) and possibly cloned are screened by any appropriate means in order to select the recombined polynucleotide sequences or the clones having advantageous properties as compared to the corresponding properties of the reference sequences. By advantageous property is understood to be, for example, the thermostability of

an enzyme or its ability to function under conditions of pH or of temperature or of saline concentration more adapted to an enzymatic process than the control proteins usually used for said process. For example, such a process can be an industrial process to breakdown textile fibers or bleaching paper pulps or producing flavors in the dairy industry, the processes of biocatalysis for the synthesis by an enzymatic pathway of new therapeutic molecules, etc.

According to an advantageous embodiment of the process of the invention, the polynucleotide sequence library can therefore be the result of a screening having permitted selection by any appropriate means of polynucleotide sequences having advantageous properties as compared to control sequences. The sequences selected in this way comprise a limited library.

But, it is also possible to start from a non-limited library in order to preserve the representation of the properties contained in that library.

The sequences coding for the protein or proteins having one or more advantageous properties as compared to the reference proteins are thus selected, by *in vivo* or *in vitro* screenings, and can be used to form a new library for a possible repeating of the process of the invention. One advantageous embodiment of the process of the invention therefore consists of using as the library several polynucleotide sequences selected after a first implementation of the process of the invention, possibly mixed with other polynucleotide sequences. Among the screening techniques which can be applied to each of the clones of step (e), the screening techniques *in vitro* give rise to the advantage of being free of problems of cellular physiology, and of any drawbacks tied to the *in vivo* expression cloning. Moreover, this type of screening is easily automated, which permits screening a higher number of recombined polynucleotide sequences.

The invention also relates to a recombined polynucleotide sequence obtained by a process according to the invention, as well as to a vector

containing such a recombined polynucleotide sequence, a cellular host transformed by a recombined polynucleotide sequence or by a vector of the invention, as well as a protein coded by this recombined polynucleotide sequence. The invention includes as well the corresponding libraries of recombined polynucleotide sequences, vectors, cellular hosts, or proteins.

Other advantages and features of the invention will appear from the examples of carrying out the invention, which follow and which are referred to in the attached drawings in which:

Figure 1 is a schematic representation of the processes of the prior art corresponding respectively to DNA-shuffling (figure 1A) and to StEP (figure 1B).

Figure 2 is a schematic representation of an example of carrying out the process of the invention and of certain of its variations and applications.

Figure 3 represents the positions of the ten zones of mutations (*Pvu* II and *Pst* I) carried by each mutant of the *ponB* gene used for the examples of the implementation of the invention.

Figure 4 represents the position of the primers used as compared to the sequence of the *ponB* gene.

Figure 5 represents the migration on agarose gel of RLR and of PCR reaction products of these RLR reactions.

Figure 6 represents the position of the mutations as compared to the restriction fragments.

I- EXAMPLE

The process of the invention was put into practice starting from a library of gene mutants of *ponB*, coding for the PBP1b of *E. coli* (1). Ten

mutants of this gene were used. The gene sequence of each mutant differs from that of the native gene by a non homologous zone of thirteen to sixteen bases in length resulting from the substitution of five initial codons by five alanine codons according to the technique described by Lefèvre et al. (8).

5

The substitution carried by each mutant is characterized by the presence of a unique site of the restriction enzyme *Pvu II* surrounded by two *Pst I* enzyme sites, which permits the mutants to be distinguished from each other by their digestion profile with these restriction endonucleases. Figure 3
10 represents the positions of the ten zones of mutations (*Pvu II* and *Pst I*) carried by each mutant.

After PCR amplification of the genes of the ten mutants, the PCR products were purified, mixed in equimolar quantity in order to form the library.
15 The polynucleotide sequences of this library were digested with the restriction enzymes *Hinf I* and *Bsa I*, in such a way as to generate libraries of restriction fragments. The restriction fragments were then incubated with various amounts of the wild type template, at different quantities, in the presence of a thermostable ligase. After several denaturation/hybridization/ligation cycles, a
20 fraction of the reaction mixture was used to carry out a PCR amplification with a couple of primers specific to the 5' and 3' ends of the genes of the mutants and non-specific to the 5' and 3' ends of the wild type template. The amplification product was cloned and the obtained clones were analyzed for their digestion profile with the *Pvu II* or *Pst I* restriction endonucleases. The
25 obtained profiles permitted the determination of which fragment(s) of the mutants had been able to be recombined with the others in order to form an entire gene.

II MATERIALS

30

1) Strains and plasmids

The strain MC1061 (F^- *araD*139, Δ (*ara-leu*)7696, *galE*15, *galK*16, Δ (*lac*)X74, *rpsL* (Str^R), *mcrA* *mcrB*1, *hsdR*2 ($r_K^- m_K^+$)) is derived from *Escherichia coli* K12.

5 The vector pARAPONB stems from the vector pARA13 (3) in which the *ponB* gene carrying a thrombin-cutting site (9) was introduced between the restriction sites *Nco* I and *Nar* I. The vector pET26b+ is one of the pET vectors developed by Studier and Moffatt (13) and commercialized by NOVAGEN Corporation.

10
2) Oligonucleotides

The oligonucleotides were synthesized by ISOPRIM corporation (Toulouse). The oligonucleotide sequences are reported in Table I below.

15 Table I

sub a1 >	Oligo N	5' AGTGACTAGGCATGGGCGGGGAATGACCGCGGAGCC 3'
sub a2 >	Oligo E	5' CCGCGGGTGGAGCGGAATTGTAATTAGTAGGAAACATATCC 3'
sub a3 >	Oligo M1	5' GCGCGCTGAATATTGGGGAGAAAAAGC 3'
sub a4 >	Oligo M2	5' ACAAGGAGATGAAAAGAAAGGGTTAATATC 3'
sub a5 >	Oligo A1	5' AGTGACTAGGCATGGCC 3'
sub a6 >	Oligo A2	5' CCGCGGGTGGAGCGGAATTG 3'

20 3) Reagents

The restriction and modification enzymes cited in Table II below were used according to the recommendations of the suppliers.

25 Table II

Enzyme	Concentration	Supplier
<i>NcoI</i>	10 U/ μ l	New England Biolabs
<i>PstI</i>	20 U/ μ l	New England Biolabs
<i>Eco RI</i>	20 u/ μ l	New England Biolabs
<i>Bsa I</i>	5 U/ μ l	New England Biolabs
<i>Hinf I</i>	10 U/ μ l	New England Biolabs
<i>Pvu II</i>	10 U/ μ l	New England Biolabs
T4 DNA ligase	400 U/ μ l	New England Biolabs
Taq DNA polymerase	5 U/ μ l	PROMEGA
AMPLIGASE	100 U/ μ l	EPICENTRE

The buffers used are reported in Table III below

Buffers	Composition
T	Tris HCl 10 mM, pH 8.0
Polymerization 20X	Tris HCl 100 mM pH 8.3, MgCl ₂ 15 mM, KCl 500 mM, 1.0% TRITON X100®
Restriction A 10X	500 mM NaCl, 100 mM Tris HCl pH 7.9, 100mM MgCl ₂ , 10mM DTT,
Restriction B 10X	1 M NaCl, 500 mM Tris HCl pH 7.9, 100 mM MgCl ₂ , 10 mM DTT
Restriction C 10X	500 mM NaCl, 1 M Tris HCl pH 7.5, 100 mM mM MgCl ₂ , 0.25% TRITON X100®
AMPLIGASE 10X	200 mM Tris HCl pH 8.3, 250 mM KCl, 100 mM MgCl ₂ , 5 mM NAD, 0.1% TRITON X100®
Ligation 10X	500 mM Tris HCl pH 7.5, 100 mM MgCl ₂ , 100 mM DTT, 10 mM ATP, 250 μ g/ml BSA

The wild type *ponB* gene was amplified by a PCR reaction step by using as primers the oligonucleotides M1 and M2 (Fig. 4). Five PCR reactions were prepared by adding 50 ng of pPONBPBR plasmid carrying the wild type gene (7) to a mixture containing 10 µl of polymerization buffer, 10 µl of dNTPs 2mM, 20 pmol of each oligonucleotide M1 and M2, and 5U of Taq DNA polymerase, in a final volume of 100 µl. These mixtures were incubated in Perkin-Elmer 9600 Thermocycler according to the following program: (94 °C – 2 min.) – (94°C 15 sec. - 60°C 30 sec. -72°C 1 min.) x 29 cycles – (72°C – 3 min.).

The product of the five PCR was mixed and loaded on a 1% TBE agarose gel. After migration and staining of the gel with ethidium bromide, the band at 2651 bp, corresponding to the *ponB* gene amplification product surrounded by two fragments of 26 bp and 90 bp respectively, was visualized by trans-illumination under ultraviolet, and cut out with a scalpel in order to be purified with the QIAquick system (QIAGEN). All the DNA thus purified was eluted in 120 µl of buffer T. The concentration of this DNA was approximately 100 ng/µl as measured by its absorbance at 260 nm.

IV PREPARATION OF THE LIBRARY

1) Amplification of the mutant genes

The genes of the ten mutants were separately amplified by a PCR reaction with oligonucleotides N and E. These oligonucleotides introduce respectively the restriction sites *Nco I* and *Eco RI*, permitting the cloning of the products obtained with these two sites.

Each PCR reaction was prepared by adding 50 ng of the plasmid carrying the mutant gene to a mixture containing 10 µl of polymerization buffer, 10 µl of dNTPs 2mM, 20 pmol of each oligonucleotide N and E, and 5U of Taq DNA polymerase, in a final volume of 100 µl. This mixture was

incubated in a Perkin-Elmer 9600 thermocycler according to the following program: (94°C – 2 min.) – (94°C 15 sec. - 60°C 30 sec. - 72°C 1 min.) x 29 cycles – (72°C – 3 min.).

5 The specificity of the genetic amplification was verified by restriction profile with the *Pvu II* endonuclease, by incubating 5 µl of each PCR product 1 hour at 37 °C in a mixture containing 3 µl of restriction buffer A and 5U of the *Pvu II* enzyme in a final volume of 30 µl. 15 µl of that digestion reaction were loaded on a TBE 1% agarose gel. After migration and staining with ethidium
10 bromide, the gel was exposed to ultraviolet. The visualization of the restriction fragments permitted confirmation of the specificity of the genetic amplification of each mutant gene.

15 In parallel, 3 µl of each PCR reaction were loaded on a TBE 1% agarose gel . After migration, the gel was treated as above. The intensity of each band permitted the assessment that the genetic amplifications had the same yield.

20 2) Creation of libraries of restriction fragments.

50 µl of each of the ten PCR were mixed and loaded on a 1% TBE agarose gel. After migration and staining with ethidium bromide, the band at 2572 bp, corresponding to the amplification product of the genes of the ten mutants, was cut out with a scalpel and purified with the Quiaquick system (QIAGEN).
25 Allthe DNA thus purified was eluted in 120 µl of buffer T. The concentration of this DNA was approximately 100 ng/µl according to its absorbance at 260 nm.

30 In order to generate the libraries of restriction fragments, 100 µl of this DNA were incubated for one hour at 50°C in a mixture containing 12 µl of restriction buffer B, 1.2 µl of BSA (at 10 mg/ml), 25 U of the enzyme *Bsa I* and 4 µl of water. Then, 2 µl of restriction buffer B, 2 µl of BSA (at 1 mg/ml), 50 U of the enzyme *Hinf I* and 11.5 µl of water were added to the mixture, which

was incubated for one hour at 37 °C. The digestion mixture was purified on a QIAquick column (QIAGEN), and eluted with 30 µl of buffer T. 1 µl of this eluate was loaded on a 1% TBE agarose gel in order to verify that the digestion had been total, and that it had generated 6 restriction fragments, and consequently six libraries of fragments, of 590 bp, 500 bp, 472 bp, 438 bp, 298 bp and 274 bp. The concentration of this DNA was approximately 250 ng/µl according to its absorbance at 260 nm.

V RLR (Recombining Ligation Reaction).

The RLR reaction (Recombining Ligation Reaction) was carried out by incubating determined quantities of restriction fragments *Hinf I* – *Bsa I* from the genes of ten mutants with the complete template (i.e., the wild type *ponB* gene), in the presence of a thermostable DNA ligase. The table IV below reports the composition of the mixtures for RLR.

Table IV

	RLR 1	RLR 2	RLR 3	RLR 4	T-
Fragments <i>Hinf I</i> – <i>Bsa I</i> of ten mutants (100 ng/µl)	0.5 µl	1 µl	2 µl	5 µl	5 µl
Wild type <i>ponB</i> template (100 ng/µl)	0.6 µl	1.2 µl	2.4 µl	6 µl	6 µl
AMPLIGASE 10X Buffer	2 µl	2 µl	2 µl	2 µl	2 µl
AMPLIGASE (25 U/µl)	1 µl	1 µl	1 µl	1 µl	-
H ₂ O	qsp 20 µl	qsp 20 µl	qsp 20 µl	qsp 20 µl	qsp 20 µl

The negative control is identical to the reaction of RLR4, but does not contain thermostable DNA ligase. These different mixtures were covered with a drop of mineral oil and incubated in a Perkin-Elmer 9600 thermocycler in 200 µl microtubes according to the following program: (94 °C, 5 min.) – (94°C, 1 min. - 65°C, 4 min.) x 35 cycles.

10 µl of each RLR reaction were then added to a PCR reaction mixture containing 10 µl of polymerization buffer, 10 µl of 2 mM dNTPs, 40 pmol of each oligonucleotide A1 and A2, and 5 U of Taq DNA polymerase in a final volume of 100 µl. This mixture was incubated in a Perkin-Elmer 9600 thermocycler according to the following program: (94°C, 5 min.) – (94°C, 30 sec. - 46°C, 30 sec. - 72°C, 1 min.) x 29 cycles – (72°C, 2 min.). This PCR reaction permitted specific amplification of the ligation products formed in the course of the RLR reaction, without amplifying the template, since the oligonucleotides A1 and A2 are not able to hybridize with the template (it), as shown in Figure 4.

5 µl of each RLR reaction and 10 µl of each of the previous PCR reactions were loaded on a 1% TBE agarose gel. After staining with ethidium bromide, the gel was exposed to ultraviolet light, as shown in Figure 5.

The analysis of this gel reveals that only the reaction of RLR4 contains, as the negative control, restriction fragments still visible (tracks 4 and 5).

25

The absence of PCR product for the negative control (track 10) reveals not only that the PCR reaction is specific (no amplification of the complete template), but also that the restriction fragments present in the mixture cannot be substituted for the primers to generate a contaminant PCR product under the chosen conditions. In parallel, the presence of a unique band at about 2500 bp in tracks 6, 7 and 8 demonstrates that an RLR product was able to be amplified by PCR for the RLR1, 2 and 3 reactions. These three RLR

30

reactions therefore permitted the regeneration of one or more of the complete genes starting from six libraries of restriction fragments.

5 VI ANALYSIS OF THE AMPLIFICATION PRODUCTS OF THE
RLR REACTIONS

1) Cloning

10 The PCR amplification products of the RLR 1, 2 and 3 reactions were purified with the Wizard PCR Preps system (PROMEGA) and eluted in 45 μ l of buffer T. 6 μ l of each purified PCR were incubated 1 hour at 37 °C in a mixture containing 3 μ l of restriction buffer C, 3 μ l of BSA (1 mg/ml), 20 U of the *Eco* RI enzyme, 10 U of the *Nco* I enzyme and 15 μ l of water.

15 In parallel, two vectors (pARAPONB and pET26b+) were prepared for the cloning. These vectors were linearized by incubating 3 μ g of these plasmids for 2 hours at 37 °C, in a mixture containing 3 μ l of restriction buffer C, 3 μ l of BSA (1 mg/ml), 20 U of the *Eco* RI enzyme, 10 U of the *Nco* I enzyme and 19 μ l of water.

20 The linearized vectors as well as the digested PCR were purified on a TBE 1% agarose gel with the QIAquick system (QUIAGEN). Each vector or each digested PCR was eluted in 30 μ l of buffer T.

25 The ligation of each PCR digested with each of the vectors was carried out according to the conditions described in table V below, and incubated at 16 °C for 16 hours.

Table V

	Ligation with the vector pARAPONB				Ligation with the vector pET26b+			
	LpAR1	LpAR2	LpAR3	TLpAR	LpET1	LpET2	LpET3	TLpET

PCR amplification RLR 1 digested <i>Nco I – Eco RI</i>	4 µl	-	-	-	4 µl	-	-	-
PCR amplification RLR 2 digested <i>Nco I – Eco RI</i>	-	4 µl	-	-	-	4 µl	-	-
PCR amplification RLR 3 digested <i>Nco I – Eco RI</i>	-	-	4 µl	-	-	-	4 µl	-
Vector pARAPONB digested <i>Nco I – Eco RI</i>	1 µl	1 µl	1 µl	1 µl	-	-	-	-
Vector pET26b+ digested <i>Nco I – Eco RI</i>	-	-	-	-	1 µl	1 µl	1 µl	1 µl
Ligation Buffer	2 µl	2 µl	2 µl	2 µl	2 µl	2 µl	2 µl	2 µl
Ligase	1 µl	1 µl	1 µl	1 µl	1 µl	1 µl	1 µl	1 µl
H ₂ O	12 µl	12 µl	12 µl	16 µl	12 µl	12 µl	12 µl	16 µl

200 µl of chimiocompetent MC1061 cells (4) were transformed with 10 µl of each ligation by a thermal shock (5), and the cells thus transformed were spread over a selection medium.

5

No clone was obtained after transformation of ligation controls TLpAR and TLpET, thus indicating that the *Nco I – Eco RI* vectors pARAPONB and pET26b+ cannot undergo an intramolecular ligation.

10

2) Screening by PCR

15

A first screening of the clones obtained after transformation of the ligations with the vector pARAPONB was carried out by PCR. 42 colonies, 14 from each ligation LpAR1, LpAR2 and LpAR3, were resuspended individually in a PCR mixture containing 5 µl of polymerization buffer, 40 pmol of each oligonucleotide A1 and A2, 5 µl of 2 mM dNTPs and 5U of Taq DNA polymerase in a final volume of 50 µl. A negative control was obtained by

adding to the PCR mixture 50 ng of the plasmid pBR322 in place of the colony. These 43 tubes were incubated in a Perkin-Elmer 9600 thermocycler according to the following program: (94°C, 5 min.) – (94°C, 30 sec. - 46°C, 30 sec. - 72°C, 1 min.) x 29 cycles – (72°C, 2 min.). 5 µl of each of these PCR reactions were then incubated for 1 hour at 37 °C in a mixture containing 2 µl of restriction buffer A, 2 µl of BSA (1 mg/ml) and 5 U of the restriction enzyme *Pvu II* in a final volume of 20 µl.

10 µl of each of these digestions were loaded on a TBE 1% agarose gel in parallel with 5 µl of each non-digested PCR (thus avoiding possible confusion of non-specific bands of the PCR with a fragment obtained by restriction digestion). After migration and staining of this gel with ethidium bromide, the bands resulting from the digestion by the enzyme *Pvu II* were analyzed in order to determine which fragment(s) of initial mutants was/were associated with the others in order to reconstruct an entire gene. This screening reveals the presence of 27 genes carrying one mutation, 7 genes carrying two mutations and 8 genes no longer carrying any mutation.

3) Screening by plasmidic DNA miniprep

20

The second screening was effected by carrying out an extraction of the plasmidic DNA (5) from 21 clones resulting from the transformation of the ligations with the vector pET26b+ (7 clones of each ligation). 5 µl of the plasmidic DNA thus obtained for each clone were incubated for 1 hour at 37 °C in a mixture containing 1 µl of restriction buffer C, 6 U of the enzyme *Pst I*, 3 U of the enzyme *Nco I* and 6 U of the enzyme *Eco RI* in a final volume of 10 µl. 5 µl of each of these digestions were loaded on a TBE 1% agarose gel. After migration and staining of this gel with ethidium bromide, the bands resulting from the digestion by the *Pst I* enzyme were analyzed in order to determine which fragment(s) of the initial mutants had associated with the others in order to reconstruct an entire gene. This screening reveals the

presence of 13 genes carrying a mutation, 5 genes carrying two mutations and 3 genes no longer carrying a mutation.

4) Statistical Analysis of the recombinations.

5 According to the position of each mutation as compared to the cutting sites of the enzymes *Hinf I* and *Bsa I*, as represented in Figure 6, it is possible to calculate the probability of obtaining in the course of the RLR reaction the creation of a gene carrying 0, 1, 2, 3, or 4 of the mutations of the initial genes.

10 Thus, by considering that the RLR reaction is totally random the probabilities P are as follows:

$$P(0 \text{ mutation}) = \prod_{i=6}^9 \left(\frac{i}{10} \right) = 30.24\%$$

15 $P(1 \text{ mutation}) = \sum_{n=1}^4 \left[\frac{n}{10-n} \prod_{i=1}^4 \left(\frac{10-i}{10} \right) \right] = 44.04\%$

$$P(2 \text{ mutations}) = \sum_{n=1}^4 \left[\sum_{a=1}^{4-n} \left(\frac{10-a}{a} \right) \left(\frac{10-(a+n)}{a+n} \right) \prod_{i=1}^4 \left(\frac{i}{10} \right) \right] = 21.44\%$$

$$P(3 \text{ mutations}) = \sum_{n=1}^4 \left[\left(\frac{10-n}{n} \right) \prod_{i=1}^4 \left(\frac{i}{10} \right) \right] = 4.04\%$$

20 $P(4 \text{ mutations}) = \prod_{i=10}^4 \left(\frac{i}{10} \right) = 0.24\%$

The two screenings carried out give results close to these statistical predictions, as reported in table VI below, thus indicating that the RLR
 25 reaction is quasi-random. A slightly higher proportion of genes carrying one mutation, to the detriment of the genes carrying zero mutation, is observed. This phenomenon could be attributed to a weak toxicity of the *ponB* gene already observed and to the slight of expression leakage of vectors pARAPONB and pET26b+, which would favor the selection of genes carrying
 30 an inactivating mutation.

Table IV

%	0 mutation	1 mutation	2 mutations	3 mutations	4 mutations
Statistics	30.24	44.04	21.44	4.04	0.24
PCR Screening	21	63	16	0	0
Mini- preparation Screening	14	62	24	0	0

09/23/09

BIOGRAPHICAL REFERENCES

- 1) Broome-Smith J.K., Edelman Al, Yousif S. and Spratt B.G.,
(1985), The nucleotide sequence of the *ponA* and *ponB* genes
encoding penicillin-binding proteins 1A and 1B of *Escherichia*
coli K12, Eur. J. Biochem., 147, 437-446.
- 2) Caldwell R.C. and Joyce G., 1992, Randomization of genes by
PCR mutagenesis, PCR Methods and Application, 2, 28-33.
- 3) Cagnon C., Valverde V. and Masson J.-M., (1991), A new family
of sugar inducible expression vectors for *Escherichia coli*, Prot.
Eng., 4, 843-847.
- 4) Hanahan D., (1985), Techniques for transformation of
Escherichia coli, in DNA cloning: a practical approach, Glover
D.M. (ed), IRL Press, Oxford vol I, 109-135.
- 5) Maniatis T., Fristch E.F. and Sambrook J., (1982), Molecular
cloning. A laboratory Manual, Cold Spring Harbor Laboratory,
Cold Spring Harbor, NY.
- 6) Landt et al., Gene, 96, 125-128, 1990.
- 7) Lefèvre F., Topological Analysis of the Penicillin Binding Protein
1b of *Escherichia coli*, 1997, Thèse.
- 8) Lefèvre F., Rémy M.H. and Masson J.M., 1997 (a), Alanine-
stretch scanning mutagenesis: a simple and efficient method to
probe protein structure and function, Nuc. Acids Res., 25, 447-
448.

- 5
- 9) Lefèvre F., Rémy M.H. and Masson J.M., 1997 (b),
Topographical and functional investigation of *Escherichia coli*
Penicillin-Binding Protein 1b by alanine stretch scanning
mutagenesis, J. Bacteriol., 179, 4761-4767.
- 10
- 10) Lyamichev V., Mast A.I., Prudent J.R., Kaiser M.W., Takova T.,
Kwiatkowski R.W., Sander T.J., de Arruda M., Arco D.A., Neri
B.P. and Brown M.A.D., 1999, Polymorphism identification and
quantitative detection of genomic DNA by invasive cleavage of
oligonucleotide probes, Nature Biotechnology, 17, 292-296.
- 11) Picard et al., Nuc. Acids Res., 22, 2587-2591, 1994.
- 12) Stemmer W.P.C., (1994), Rapid evolution of a protein *in vitro* by
DNA shuffling, Nature, 370, 141-144.
- 13) Studier F.W. and Moffatt B.A., 1986, Use of bacteriophage T7
RNA polymerase to direct selective high-level expression of
cloned genes, J. Mol. Biol, 189, 113-130.
- 14) Zhao, H., Giver L., Shao Z., Affholter J.A. and Arnold F., 1998,
Molecular evolution by staggered extension process (StEP) in
vitro recombination, Nature Biotech., 16, 258-261.
- 20